Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AutoSynVax in advanced cancer
NCT02992977Phase 1Terminated
- Sponsor
- Agenus Inc.
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AutoSynVax in cancer, sponsored by Agenus Inc. Primary endpoints: Incidence of Treatment-Emergence Adverse Events and Recommended dose for further development. Started Jan 2017; status: terminated.
02
Drugs
AutoSynVax
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02992977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992977.